PDS Biotechnology Corporation
NASDAQ:PDSBBiotechnology
+$0.01 today
- Market cap
- $51.58M
- Beta
- 1.56
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.60
Volume 5.25M
Average 1.04M
PDSB Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
PDS Biotechnology CorporationNASDAQ: PDSB
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 55.5M shares rose 37.0% year over year, ahead of the +29.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 19.6% from the prior quarter. Over 3 fiscal years it compounded at +17.5% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +37.0% holds above the trailing-twelve-month pace of +29.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 46.38M USD
- Year-over-year change
- +27.2%
- 4-year CAGR
- +16.0%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.38M | +27.2% |
| FY2024 | 2024-12-31 | 36.45M | +17.8% |
| FY2023 | 2023-12-31 | 30.95M | +8.2% |
| FY2022 | 2022-12-31 | 28.6M | +11.7% |
| FY2021 | 2021-12-31 | 25.6M | — |
Weighted Avg Shares vs competitors
How PDSB compares with its peers on the latest reported figures
- PDSB's LTM Mar 2026 weighted avg shares of 48.66M shares is the 2nd highest of the 6 companies compared; the peer median is 25.76M shares.
- Its year-over-year change of +29.4% is the 3rd highest of 6, against a peer median of +22.3%.
- Over three fiscal years its annual growth of +17.5% compares with a peer median of +14.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 65.27M | +1380.9% | +249.6% | |
| LTM Mar 2026 | 48.66M | +29.4% | +17.5% | |
| LTM Jun 2026 | 31.26M | +0.3% | +8.9% | |
| LTM Mar 2026 | 25.76M | +22.3% | +14.0% | |
| LTM Mar 2026 | 22.96M | +82.7% | +36.0% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | 13.55M | +1.4% | +0.4% |
| Peer median (excluding PDSB) | 25.76M | +22.3% | +14.0% | |
Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 57.33K | 59.79K | 0 |
| Gross Profit | 0 | 0 | (57.33K) | (59.79K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 11.25M | 29.43M | 27.76M | 22.57M | 19.03M |
| Selling, General & Admin | 10.18M | 12.24M | 15.28M | 13.7M | 12.52M |
| Operating Expenses | 21.44M | 41.67M | 43.05M | 36.26M | 31.54M |
| Depreciation & Amortization | 5.36K | 86 | 57.33K | 59.79K | 21.84K |
| EBITDA | (21.43M) | (40.74M) | (40.09M) | (33.75M) | (30.3M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.44M) | (41.67M) | (43.05M) | (36.32M) | (31.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4.35K | 935.18K | 2.9M | 2.52M | 1.22M |
| Interest Expense | 0 | 1.32M | 4.21M | 4.67M | 5.34M |
| Other Income / Expenses | 4.35K | (381.34K) | (1.3M) | (2.16M) | (4.12M) |
| Income Before Tax | (21.43M) | (42.05M) | (44.35M) | (38.48M) | (35.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (4.52M) | (1.2M) | (1.41M) | (869.17K) | (1.17M) |
| Net Income | (16.92M) | (40.85M) | (42.94M) | (37.61M) | (34.5M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) |
| EPS (Diluted) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) |
| Weighted Avg Shares | 25.6M | 28.6M | 30.95M | 36.45M | 46.38M |
| Weighted Avg Shares (Diluted) | 25.6M | 28.6M | 30.95M | 36.45M | 46.38M |
PDS Biotechnology Corporation
NASDAQ:PDSB
Intrinsic Alpha fair value
Locked
Current Price
$0.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.